92 related articles for article (PubMed ID: 19939780)
1. [Place of autologous and allogeneic hematopoietic stem cell transplantation in ovarian cancer].
Nayl B; Cabrespine-Faugeras A; Maliki Y; Bay JO
Bull Cancer; 2009 Dec; 96(12):1225-32. PubMed ID: 19939780
[TBL] [Abstract][Full Text] [Related]
2. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
3. The role of hematopoietic stem cells in the treatment of ovarian cancer.
Perillo A; Pierelli L; Scambia G; Leone G; Mancuso S
Panminerva Med; 2002 Sep; 44(3):197-204. PubMed ID: 12094133
[TBL] [Abstract][Full Text] [Related]
4. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
5. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study.
Gonçalves A; Delva R; Fabbro M; Gladieff L; Lotz JP; Ferrero JM; Linassier C; Cottu PH; Viens P; Extra JM
Bone Marrow Transplant; 2006 Apr; 37(7):651-9. PubMed ID: 16501596
[TBL] [Abstract][Full Text] [Related]
6. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. [General characteristics, basis and procedures for high dose chemotherapy procedures supported by hemopoietic stem cell transplantation].
Skotnicki AB; Zawirska D; Nowak W
Przegl Lek; 1999; 56 Suppl 1():10-6. PubMed ID: 10494176
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
13. Hematological toxicity of salvage treatment after high-dose chemotherapy and conventional chemotherapy of ovarian cancer.
Vuento MH; Salmi TA; Remes KJ; Grénman SE
Anticancer Res; 2002; 22(2B):1151-5. PubMed ID: 12168916
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer.
Cure H; Legros M; Fleury J; Dauplat J; Condat P; Choufi B; Chollet P; Plagne R
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S34-5. PubMed ID: 8899168
[No Abstract] [Full Text] [Related]
16. High dose chemotherapy with cisplatin, VP16 and carboplatin with stem cell support in patients with advanced ovarian cancer.
Pierelli L; Menichella G; Foddai ML; Serafini R; Vittori M; Paoloni A; Benedetti Panici P; Scambia G; Baiocchi G; Greggi S
Haematologica; 1991 Mar; 76 Suppl 1():63-5. PubMed ID: 1677915
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
18. [Intensive chemotherapy with autologous stem cell transplantation in ovarian cancers: analysis of 67 patients treated at the Paoli-Calmettes Institute and a review of the literature].
Viens P; Bertucci F; Gravis G; Camerlo J; Cowen D; Delpero JR; Conte M; Jacquemier J; Faucher C; Blaise D; Bardou VJ; Chabannon C; Blanc AP; Jaubert D; Maraninchi D
Bull Cancer; 1997 Sep; 84(9):869-76. PubMed ID: 9435808
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution.
Bertucci F; Viens P; Gravis G; Blaise D; Faucher C; Oziel-Taoeb S; Bardou VJ; Jacquemier J; Delpero JR; Maraninchi D
Anticancer Res; 1999; 19(2B):1455-61. PubMed ID: 10365123
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
